SP16
Inflammatory Diseases (Acute, Chronic, Orphan)
Pre-clinicalActive
Key Facts
Indication
Inflammatory Diseases (Acute, Chronic, Orphan)
Phase
Pre-clinical
Status
Active
Company
About Serpin Pharma
Serpin Pharma is a private, pre-revenue biotech developing SP16, a first-in-class peptide therapeutic targeting the LRP1 receptor to resolve harmful inflammation. With a robust IP estate covering composition of matter, the company is advancing SP16 through pre-clinical and clinical trials for multiple inflammatory indications. The leadership team combines scientific, clinical, and business expertise, positioning the company to address a massive anti-inflammatory therapeutics market projected to exceed $130 billion.
View full company profile